Filing Flows › Intellia Therapeutics (NTLA) › Recalls, complaints & regulation
Intellia Therapeutics (NTLA): clinical trials
Intellia Therapeutics (NTLA) beyond its filings: 6 active clinical trials.
Intellia Therapeutics' latest quarter
Intellia Therapeutics, Q3 2026: revenue $7.2M (-48% year over year), net loss $127M, operating cash flow −$85.4M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Intellia Therapeutics have?
6 active studies on ClinicalTrials.gov, 3 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.